In the treatment landscape of ischemic stroke and amyotrophic lateral sclerosis (ALS), oxidative stress is one of the core pathological mechanisms driving neuronal death. Edaravone API powder is a potent free radical scavenger designed specifically to address this issue. Chemically, it is a pyrazolone derivative with the molecular formula C₁₀H₁₀N₂O and a molecular weight of 174.20 g/mol. Edaravone does not rely on complex metabolic activation; it directly neutralizes reactive oxygen species such as hydroxyl radicals and peroxynitrites by donating hydrogen atoms or electrons, thereby protecting neuronal membrane lipids, mitochondrial DNA, and proteins from oxidative damage.
🧪 The simple framework of pyrazolone
Chemically, Edaravone API powder is a pyrazolone compound, belonging to the heterocyclic aromatic free radical scavenger family. Its core structure consists of a five-membered nitrogen-containing heterocycle-pyrazolone-with a methyl group at position 3 and a phenyl group at position 5. This "methyl-pyrazolone-phenyl" three-module structure is the chemical basis for its free radical scavenging activity. The introduction of the phenyl group increases the molecule's lipophilicity, enabling it to effectively penetrate cell membranes and reach lipid-rich subcellular structures such as mitochondrial membranes.
Physically, high-purity Edaravone API powder is a white to off-white crystalline powder, typically requiring a purity of 98% to 99%. Its melting point is between 126-129°C, and it exhibits good chemical stability under dry conditions at room temperature. This compound is soluble in dilute acidic or dilute alkaline aqueous solutions, but has low solubility in neutral water; this characteristic necessitates the use of pH adjustment or solubilization techniques in formulation development.
Regarding stability, Edaravone is relatively sensitive to light and heat; prolonged exposure to light or high temperatures may lead to oxidation and discoloration. The supplier recommends storage at room temperature, in a sealed, dark, and dry environment. In terms of quality control, pharmacopoeia standards require an active pharmaceutical ingredient (API) content of no less than 98.5%, with key impurities including byproducts from the synthesis process and oxidative degradation products.
The powder exhibits excellent processing performance: industrially produced crystals are fine and uniform in size, with a concentrated particle size distribution, a small angle of repose, and excellent flowability. During the mixing, filtration, and freeze-drying processes in injectable formulation production, material transport is smooth, with no agglomeration or wall adhesion. It has low hygroscopicity and can be stably stored for 3 years in a sealed, dry environment, oxidizing only slowly under strong light and high temperatures, facilitating convenient warehousing management.
Its molecular safety attributes are well-defined: it exhibits low cytotoxicity to normal cells at therapeutic doses and has no genotoxicity. It is primarily metabolized by the liver in vivo, with inactive metabolites, and is excreted by the kidneys, posing no risk of accumulation. The structure contains no easily hydrolyzed groups, ensuring stable purity during long-term storage and guaranteeing the long-term efficacy of the formulation.
⚙️ Neuroprotective mechanisms of free radical scavenging + anti-inflammatory and anti-apoptotic effects
Once in the body, Edaravone API powder rapidly penetrates the blood-brain barrier due to its amphiphilic nature, accumulates in brain tissue, and exerts neuroprotective effects through a triple-core pathway. Its primary mechanism is the efficient scavenging of free radicals, including superoxide anions, hydroxyl radicals, and lipid peroxides, with an EC₅₀ as low as 0.8–1.2 μM, making it one of the most potent small-molecule free radical scavengers currently available.
In ischemic stroke scenarios, brain hypoxia triggers a massive burst of reactive oxygen species (ROS), leading to lipid peroxidation, cell membrane rupture, and neuronal apoptosis. Edaravone converts highly reactive ROS into stable, non-toxic products through single-electron transfer to free radicals, oxidizing them into diketone compounds and hydrolyzing them for excretion, thus blocking the oxidation chain reaction and protecting the integrity of brain cells and vascular endothelium.
For amyotrophic lateral sclerosis (ALS), the core pathology is oxidative stress damage and apoptosis of motor neurons. Edaravone activates the Nrf2/HO-1 antioxidant pathway, inhibits the NFκB inflammatory pathway, and reduces the release of inflammatory factors; simultaneously, it downregulates the expression of apoptotic proteins, inhibits delayed neuronal death, and delays motor function decline in ALS patients.
It has significant protective effects on cerebrovascular systems: it can inhibit matrix metalloproteinase 9 (MMP-9) activity, reduce blood-brain barrier damage and cerebral edema, improve cerebral blood flow in ischemic areas, and reduce infarct volume. Clinical data show that acute-phase administration can significantly increase the content of N-acetylaspartate (NAA, a marker of viable neurons) in the brain and improve neurological deficit scores.
Its mechanism of action is highly selective: it preferentially clears excess ROS under pathological conditions without interfering with normal physiological signals; it does not affect human DNA polymerase, resulting in low genotoxicity risk. Its short half-life in vivo allows for effective concentration maintenance with 1–2 daily doses, avoiding cumulative toxicity; it can synergistically enhance the effects of thrombolytic and antiplatelet drugs without increasing the risk of bleeding.
💊 Core treatment for stroke and ALS, expanded to multiple scenarios
Edaravone API Powder primary use is in the treatment of acute ischemic stroke (cerebral infarction), serving as a first-line neuroprotective agent. Administered intravenously within 72 hours of symptom onset, it can halt the progression of cerebral edema, reduce infarct size, improve neurological deficits, and decrease disability rates. The standard treatment course is 14 days, demonstrating definite efficacy and high safety.
It is also approved for amyotrophic lateral sclerosis (ALS), being the world's first ALS treatment drug. It received orphan drug approval from the US FDA in 2017 and was included in Chinese guidelines in 2019. It can delay muscle weakness decline, prolong survival, and improve quality of life. Dosage forms include intravenous injection and oral dry suspension, suitable for long-term treatment needs.
It is widely used in the perioperative period of neurosurgery: for post-traumatic brain injury, cerebral hemorrhage, and brain tumor surgery, it clears reactive oxygen species (ROS) caused by surgical stress, reduces cerebral edema and inflammatory responses, protects normal brain tissue, and reduces the risk of postoperative neurological dysfunction.
Expanding its applications to cardiovascular and metabolic complications: It serves as an adjunct treatment for myocardial ischemia and diabetic peripheral neuropathy, protecting vascular endothelium and improving microcirculation through antioxidant action; it also shows potential value in oxidative stress-related diseases such as retinopathy and Parkinson's disease.
High-purity grades are used as control standards and research tools: supplied to drug testing institutes and pharmaceutical quality control laboratories worldwide for content determination and impurity testing; in neuropharmacology laboratories, it is used as a positive control for research on oxidative stress, neuroprotective mechanisms, and drug screening for neurodegenerative diseases.
🧠Frontiers in Oral Medications and Long-Term Management of ALS
The industry and research focus surrounding Edaravone API powder is on the development of oral formulations and the optimization of long-term management of amyotrophic lateral sclerosis (ALS). Currently, commercially available edaravone formulations are all intravenous injections, requiring infusion in hospitals or specialized nursing facilities. This poses an inconvenience for ALS patients requiring long-term treatment. To address this issue, oral suspensions and orally disintegrating tablets are under development, aiming to enable home administration and improve patients' quality of life.
In the area of combination therapy for ALS, the combined use of edaravone and riluzole has entered clinical practice. The two drugs have complementary mechanisms of action-riluzole inhibits glutamate release, while edaravone scavenges oxidative stress. The combination therapy group has shown a trend of superiority over monotherapy in delaying lung function decline and prolonging survival.
Regarding the quality of active pharmaceutical ingredients (APIs) and the generic drug market, the core compound patent for edaravone has expired. High-purity, uniformly sized edaravone APIs that meet the standards of multiple pharmacopoeias are key competitive factors for generic drug companies entering the international market. Key quality control indicators include content determination, related substances, loss on drying, and heavy metal limits.
Regarding formulation process innovation, the oxidation sensitivity of edaravone requires strict nitrogen protection during the filling process of lyophilized powder injections. The development of novel pre-filled, ready-to-use dosage forms is underway, aiming to reduce clinical solution preparation steps and lower the risk of secondary contamination.
Conclusion
Edaravone API powder is a neuroprotective agent that directly scavenges hydroxyl radicals and peroxynitrites. The simplicity of its molecular structure does not hinder its powerful antioxidant efficacy. In acute ischemic stroke, it reduces infarct volume by interrupting the lipid peroxidation chain reaction; in amyotrophic lateral sclerosis (ALS), it slows functional decline by reducing the oxidative load on motor neurons.
Xi'an Faithful BioTech Co., Ltd. cordially invites European pharmaceutical companies to partner with us for high-quality, competitively priced Edaravone API powder. We offer comprehensive customer service, including detailed quotations, product specifications, and sample testing, ensuring your confidence in the quality and authenticity of our products. We also provide complete compliance documentation and regulatory support, simplifying your procurement process and ensuring smooth customs clearance in Europe.
Contact our experienced team today at allen@faithfulbio.com to discuss your specific needs and learn why leading European companies choose Faithful as their trusted Edaravone API powder supplier.
References
- National Center for Biotechnology Information. (2026). Edaravone (PubChem CID 4037). PubChem.
- Sigma-Aldrich. (n.d.). Edaravone (Product No. E3310). Merck KGaA.
- Toyama Chemical Co., Ltd. (2001). Radicut (edaravone) prescribing information. Pharmaceuticals and Medical Devices Agency.
- Mitsubishi Tanabe Pharma Corporation. (2017). Radicava (edaravone) prescribing information. U.S. Food and Drug Administration.
- AbMole BioScience. (n.d.). Edaravone (M2105). Retrieved June 15, 2026.